Clinical Scorecard: This Week’s CGT News: Promising Data for In Vivo CAR T
At a Glance
| Category | Detail |
|---|---|
| Condition | B-cell malignancies, multiple myeloma, end-stage kidney disease |
| Key Mechanisms | In vivo CAR T cell therapy targeting CD19/CD20 and BCMA |
| Target Population | Patients with relapsed or refractory cancers and end-stage kidney disease |
| Care Setting | Clinical trials and transplant centers |
Key Highlights
- Phase 1 data shows complete response in 5 out of 6 patients treated with LB2501 for lymphoma.
- All 18 patients with relapsed or refractory multiple myeloma showed no signs of disease after treatment with Kelonia's CAR T therapy.
- Dual CAR T therapy enabled two patients with end-stage kidney disease to receive kidney transplants.
Guideline-Based Recommendations
Diagnosis
- Assessment of lymphoma and multiple myeloma through clinical evaluation and imaging.
Management
- Utilization of in vivo CAR T therapies for eligible patients.
Monitoring & Follow-up
- Monitoring for cytokine release syndrome and other treatment-related adverse effects.
Risks
- Potential for cytokine release syndrome in CAR T therapy recipients.
Patient & Prescribing Data
Patients with B-cell malignancies and multiple myeloma.
Higher doses of CAR T therapy show promising efficacy with manageable safety profiles.
Clinical Best Practices
- Consider dual CAR T therapy for highly sensitized kidney transplant candidates.
- Monitor patients closely for cytokine release syndrome post-CAR T therapy.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
